多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的疗效和安全性

Efficacy and safety of docetaxel combined with oxaliplatin in treatment of patients with advanced non-small-cell lung cancer

目的：观察多西他赛联合奥沙利铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效和安全性。方法：将60例晚期NSCLC病人随机分为两组,每组30例。治疗组第1天以多西他赛75 mg/m2,奥沙利铂150 mg/m2静脉滴注;对照组第1天以多西他赛75 mg/m2,顺铂80 mg/m2静脉滴注。4周为一疗程,治疗2~3个疗程。结果：治疗组病人完全缓解1例,部分缓解14例,稳定11例,进展4例,有效率50.0%;对照组病人部分缓解11例,稳定11例,进展8例,有效率36.7%。治疗组的有效率明显高于对照组（P〈0.05）。治疗组病人的卡氏评分高于对照组（P〈0.05）,但中位疾病进展时间和1年生存率无显著性差异（P〉0.05）。两种化疗方案的主要不良反应均为白细胞减少、胃肠道反应和肝功能异常,但治疗组发生率低于对照组（P〈0.05）,大部分病人能耐受。结论：多西他赛联合奥沙利铂治疗晚期NSCLC的疗效较好,病人能耐受这两种药品的不良反应,生活质量较高。

Objective：To observe the efficacy and safety of combined treatment with docetaxel and oxaliplatin in patients with advanced non-small-cell lung cancer（NSCLC）.Methods： Sixty patients with advanced NSCLC were randomly divided into treatment group and control group of 30 patients each.The patients in treatment group were intravenously given 75 mg/m2 docetaxel and 150 mg/m2 oxaliplatin on the first day,while the patients in control group were given 75 mg/m2 docetaxel and 80 mg/m2 cisplatin.One treatment course lasted 4 weeks and the patients received 2-3 courses.Results： In treatment group,complete remission（CR） was found in 1 case,partial remission（PR） in 14 cases,stable disease（SD） in 11 cases and progression of disease（PD） in 4 cases.In control group,PR was found in 11 cases,SD in 11 cases and PD in 8 cases.The effective rate（CR＋PR） in treatment group was significantly higher than that in control group（50.0% vs 36.7%,P0.05）.The Karnofsky performance score（KPS） in treatment group was higher than that in control group（P0.05）,but there was no significant difference in the median progression time and 1-year survival rate between the two groups.The main adverse drug reactions（ADRs） in two groups were leucopenia,gastrointestinal reactions and hepatic dysfunction.The incidence of ADRs in treatment group was lower than that in control group（P0.05）.The ADRs could be tolerated by most of the patients.Conclusion： The combined chemotherapy regimen of docetaxel and oxaliplatin has good efficacy and tolerable ADRs in patients with advanced NSCLC.It can improve the quality of life for the patients.